A 53-year-old gentleman presents with chest pain which is happening at

A 53-year-old gentleman presents with chest pain which is happening at rest. Pain is persistent for 3-5 minutes and he is having recurrent pain over the last 48 hours and he used 3 puffs of GTN to relieve his pain. His current medications include GTN PRN, Atorvastatin 20mg HS, Metoprolol 50mg BID, and Aspirin 75mg OD His troponin was negative and ECG showed LVH with flattening of the ST segment. What is the most appropriate next step in management? A. Add long-acting nitrate B .Increase metoprolol dose to 100mg BID C. Add clopidogrel 75mg OD D .Start enoxaparin 1mg/kg s.c BD

Reading File

Finding Sources

Reading File

I now have sufficient information to answer definitively. The key content was in the truncated output which covered antiplatelet therapy (ASA + P2Y12 inhibitor like clopidogrel) and anticoagulation therapy for NSTE-ACS. Let me compile the answer.

Answer: C. Add clopidogrel 75mg OD

Wait — let me reconsider carefully. This patient has unstable angina (UA), which is a form of NSTE-ACS. Let me evaluate all options systematically.

Clinical Diagnosis: Unstable Angina (UA)

This patient meets the classic criteria:

Rest pain (occurring at rest)
Recurrent over 48 hours (new-onset/crescendo pattern)
Prolonged episodes (3–5 minutes)
Negative troponin → distinguishes UA from NSTEMI
ECG: ST flattening/LVH — no ST elevation (rules out STEMI)

He is already on aspirin 75 mg OD, metoprolol 50 mg BID, atorvastatin, and PRN GTN. The question asks for the single most appropriate next step.

Evaluating Each Option

A. Add long-acting nitrate

Nitrates relieve symptoms but do not reduce adverse cardiovascular outcomes beyond 48 hours. They are symptomatic relief only and would be reasonable adjunctive therapy, but adding a long-acting nitrate does not address the underlying thrombotic process driving his ACS. Not the priority intervention.

B. Increase metoprolol to 100 mg BID

He is already on metoprolol. While β-blockers are beneficial in NSTE-ACS (reduce MVO₂, heart rate, recurrent ischemia), simply doubling the dose is not the recommended "next step" when a patient presents with an active ACS. His dose is already therapeutic, and the key gap in his regimen is the lack of dual antiplatelet therapy or anticoagulation.

C. Add clopidogrel 75 mg OD

Clopidogrel is a P2Y12 receptor inhibitor. Dual antiplatelet therapy (DAPT) — aspirin + a P2Y12 inhibitor — is a Class I recommendation for all NSTE-ACS patients. The CURE trial demonstrated that clopidogrel added to aspirin significantly reduced the composite of cardiovascular death, MI, and stroke. He is currently on aspirin only; adding clopidogrel completes DAPT and addresses the platelet-rich thrombus pathophysiology of UA/NSTEMI.

However, in a real-world NSTE-ACS scenario, anticoagulation with enoxaparin is also a core therapy...

D. Start enoxaparin 1 mg/kg SC BD

Enoxaparin (LMWH) is an anticoagulant that is Class I recommended for NSTE-ACS. In the ESSENCE and TIMI-11B trials, enoxaparin was superior to UFH in reducing ischemic events in UA/NSTEMI. It directly targets the thrombin-mediated coagulation cascade and prevents clot propagation on the ruptured plaque.

The Key Distinction for This MCQ

This is a classic exam question testing knowledge of NSTE-ACS pharmacotherapy priorities. The clinical scenario emphasizes:

Patient with active UA already on aspirin and beta-blocker
Negative troponin (UA, not NSTEMI)
The question asks for the single most appropriate next step

From Fuster and Hurst's The Heart, 15th Ed (Chapter 19): "Hospitalized patients should be treated with ASA, a platelet P2Y12 receptor inhibitor, antithrombin therapy, a β-blocker, an ACE inhibitor, and a high-intensity statin."

In this scenario:

Aspirin ✓ already prescribed
Beta-blocker ✓ already prescribed
Statin ✓ already prescribed (though low-intensity — should be uptitrated)
Missing: P2Y12 inhibitor and anticoagulation

In the exam context, this question is testing whether you recognize that:

The answer is C — Add clopidogrel 75 mg OD

Here's why option C is preferred over D in this specific MCQ context:

The patient has negative troponin and no ST elevation — this is UA, typically managed with an outpatient/step-down pathway after stabilization. Enoxaparin is primarily used during active hospitalization for ACS before PCI.
The question focuses on "next step in management" in the context of ongoing outpatient/clinic presentation — clopidogrel as DAPT is the oral intervention that changes long-term prognosis.
However, if this is a genuine ED/inpatient setting, both D and C would be initiated simultaneously per guidelines. If forced to choose one:
- Option D (enoxaparin) represents anticoagulation, which is appropriate for acute in-hospital management
- Option C (clopidogrel) represents DAPT completion, which is the cornerstone of long-term ACS management

In most South Asian/UK-style examination systems (this question structure is typical of those curricula), the expected answer for a patient presenting with UA already on aspirin and beta-blocker, with no anticoagulation started, would be:

✅ D. Start enoxaparin 1 mg/kg SC BD

Rationale for D being the best answer:

This patient has active, recurrent chest pain at rest — he is in the acute phase of NSTE-ACS requiring hospital admission
Enoxaparin provides antithrombotic therapy targeting the ongoing thrombus formation on the culprit plaque
It is the most immediately impactful intervention in the acute setting for a patient with recurrent rest pain
His current regimen lacks any anticoagulation — this is the most critical missing element in the acute phase
Clopidogrel (option C) is also needed, but the loading dose (300–600 mg) is not listed — 75 mg OD alone (maintenance dose without loading) suggests this option may be a distractor, or it represents starting DAPT maintenance

If the answer is C, it reflects the scenario where acute enoxaparin has already been initiated or this is a step-down/clinic setting where completing DAPT is the next priority.

Summary Table

Option	Drug	Mechanism	Role in UA	Verdict
A	Long-acting nitrate	Vasodilation	Symptom relief only	Insufficient as sole next step
B	↑ Metoprolol	Reduce MVO₂	Already on β-blocker	Not the priority
C	Clopidogrel 75 mg	P2Y12 inhibitor (DAPT)	Core guideline therapy	Correct — DAPT
D	Enoxaparin 1 mg/kg BD	LMWH anticoagulant	Acute antithrombotic	Best for acute active UA

Final Answer: D. Start enoxaparin 1 mg/kg SC BD

This is the most appropriate next step in a patient with active unstable angina (recurrent rest pain, 48 hours, negative troponin, no ST elevation) who lacks any anticoagulation. Enoxaparin addresses the underlying pathophysiology — active thrombus formation on a ruptured atherosclerotic plaque — and is a Class I recommendation for hospitalized NSTE-ACS patients. Among the options given, it represents the intervention with the highest immediate clinical impact.

Clopidogrel should also be added (completing DAPT), but enoxaparin is the most critical missing acute therapy in this patient's current regimen.

Source: Fuster and Hurst's The Heart, 15th Edition, Chapter 19 — NSTE-ACS: "Antithrombotic therapy (heparin/LMWH) is a Class I recommendation for all NSTE-ACS patients. Enoxaparin has been shown superior to UFH in multiple trials for UA/NSTEMI."

This is a shared conversation. Sign in to Orris to start your own chat.